EcoDrugPlus

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSOMYG00000033071
Gene Symbol: GRIK4
1 Cross references
188 Possible Orthologues:

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSOMYG00000040978
Gene Symbol: GRM5
1 Cross references
212 Possible Orthologues:

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSOMYG00000040870
Gene Symbol: GRM5
1 Cross references
212 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 1a

Ensembl ID : ENSOMYG00000019927
Gene Symbol: GRIA1A
1 Cross references
246 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 1a

Ensembl ID : ENSOMYG00000011311
Gene Symbol: GRIA1A
1 Cross references
244 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 2b

Ensembl ID : ENSOMYG00000043010
Gene Symbol: GRIA2B
1 Cross references
204 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 2b

Ensembl ID : ENSOMYG00000017053
Gene Symbol: GRIA2B
1 Cross references
220 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 4b

Ensembl ID : ENSOMYG00000002271
Gene Symbol: GRIA4B
1 Cross references
243 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 4b

Ensembl ID : ENSOMYG00000008434
Gene Symbol: GRIA4B
2 Cross references
244 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 1a

Ensembl ID : ENSOMYG00000031564
Gene Symbol: GRIN1A
1 Cross references
198 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 1a

Ensembl ID : ENSOMYG00000042242
Gene Symbol: GRIN1A
1 Cross references
200 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 1b

Ensembl ID : ENSOMYG00000018442
Gene Symbol: GRIN1B
1 Cross references
151 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).